Key result
Patent foramen ovale is a well-established cause of stroke but is also present in 25% of healthy people, often making it an incidental finding in patients presenting with stroke.
Why the study?
Should patent foramen ovale be closed in patients with stroke outside of clinical trials?
Should patent foramen ovale be closed in patients with stroke outside of clinical trials?
Answers are grounded in this paper and cite their sources.
The editorial emphasizes that patent foramen ovale closure for stroke prevention should primarily be conducted within the context of clinical trials due to the high background prevalence of PFO.
Patent foramen ovale is a well established cause of stroke. A thrombus from venous structures can embolize through a patent foramen ovale1 and ultimately reach the brain.2 However, a patent foramen ovale can also be present in 25% of healthy people. Although detected in nearly twice as many patients with stroke of no other identifiable cause,3 a patent foramen ovale will be an incidental finding in many patients who present with stroke, given the frequency of this defect in the background population.Several devices designed to occlude a patent foramen ovale and atrial septal defects are currently on the market. . . .
No takes yet. Share an insight, caveat, or question.
S. Claiborne Johnston (2012) conducted an editorial in Patent foramen ovale and stroke. Patent foramen ovale closure was evaluated. Patent foramen ovale is a well-established cause of stroke but is also present in 25% of healthy people, often making it an incidental finding in patients presenting with stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: